Literature DB >> 20187300

CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression.

Alexander Michael Dohnal1,2, Romana Luger1, Petra Paul1, Dietmar Fuchs3, Thomas Felzmann1,2.   

Abstract

Inflammation triggered by microbial lipopolysaccharide (LPS) through Toll-like receptor (TLR) 4 in the presence of interferon (IFN)-gamma induces cytokine secretion in dendritic cells (DCs) tightly regulated by a defined differentiation program. This DC differentiation is characterized not only by a dynamic immune activating but also by tolerance-inducing phenotype associated with down-modulation of cytokines previously considered to be irreversible. CD40L on activated T cells further modifies DC differentiation. Using DNA micro-arrays, we showed down-regulated mRNA levels of TLR signalling molecules, whereas CD40/CD40L signalling molecules were up-regulated at a time when LPS/IFN-gamma-activated DCs had ceased cytokine expression. Accordingly, we demonstrated that CD40/CD40L but not TLR4 or TLR3 signalling mediated by LPS or poly (cytidylic-inosinic) acid (poly I:C) and dsRNA re-established the capacity for secreting interleukin (IL)-12 in primarily LPS/IFN-gamma-activated DCs, which have exhausted their potential for cytokine secretion. The resulting TH1 polarizing DC phenotype - which lacked accompanying secretion of the crucial immune suppressive factor IL-10 - maintained the potential for activation of cytotoxic T lymphocytes (CTLs). We therefore conclude that immune modulation is restricted to a secondary T-cell-mediated stimulus at an exhausted DC state, which prevents an immune tolerant DC phenotype. These findings impact on the rational design of TLR-activated DC-based cancer vaccines for the induction of anti-tumoural CTL responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20187300      PMCID: PMC6529981          DOI: 10.1111/j.1582-4934.2008.00584.x

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  10 in total

1.  Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.

Authors:  Alice M Nyakeriga; Jun Ying; Norah J Shire; Carl J Fichtenbaum; Claire A Chougnet
Journal:  Viral Immunol       Date:  2011-08       Impact factor: 2.257

2.  Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.

Authors:  Yohei Mineharu; A K M Ghulam Muhammad; Kader Yagiz; Marianela Candolfi; Kurt M Kroeger; Weidong Xiong; Mariana Puntel; Chunyan Liu; Eva Levy; Claudia Lugo; Adrina Kocharian; James P Allison; Michael A Curran; Pedro R Lowenstein; Maria G Castro
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

3.  A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.

Authors:  Priyadharshini Narayanan; Natalia Lapteva; Mamatha Seethammagari; Jonathan M Levitt; Kevin M Slawin; David M Spencer
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

4.  Mesothelin‑specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3‑treated self‑differentiated dendritic cells.

Authors:  Niphat Jirapongwattana; Suyanee Thongchot; Wannasiri Chiraphapphaiboon; Thaweesak Chieochansin; Doonyapat Sa-Nguanraksa; Malee Warnnissorn; Peti Thuwajit; Pa-Thai Yenchitsomanus; Chanitra Thuwajit
Journal:  Oncol Rep       Date:  2022-05-26       Impact factor: 4.136

Review 5.  Immunoregulatory Roles of Extracellular Vesicles and Associated Therapeutic Applications in Lung Cancer.

Authors:  Zhengrong Yin; Jinshuo Fan; Juanjuan Xu; Feng Wu; Yang Li; Mei Zhou; Tingting Liao; Limin Duan; Sufei Wang; Wei Geng; Yang Jin
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

6.  Role of CD40 ligation in dendritic cell semimaturation.

Authors:  Anna-Maria Gerlach; Alexander Steimle; Lea Krampen; Alexandra Wittmann; Kerstin Gronbach; Julia Geisel; Ingo B Autenrieth; Julia-Stefanie Frick
Journal:  BMC Immunol       Date:  2012-04-26       Impact factor: 3.615

Review 7.  Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Authors:  Jashodeep Datta; Erik Berk; Jessica A Cintolo; Shuwen Xu; Robert E Roses; Brian J Czerniecki
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

Review 8.  Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination.

Authors:  Tammy Oth; Joris Vanderlocht; Catharina H M J Van Elssen; Gerard M J Bos; Wilfred T V Germeraad
Journal:  Mediators Inflamm       Date:  2016-02-11       Impact factor: 4.711

9.  Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode.

Authors:  Romana Luger; Sneha Valookaran; Natalie Knapp; Caterina Vizzardelli; Alexander M Dohnal; Thomas Felzmann
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

10.  MMpred: functional miRNA--mRNA interaction analyses by miRNA expression prediction.

Authors:  Przemyslaw A Stempor; Michael Cauchi; Paul Wilson
Journal:  BMC Genomics       Date:  2012-11-14       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.